<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39311377</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4468</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>02</Day></PubDate></JournalIssue><Title>Antibodies (Basel, Switzerland)</Title><ISOAbbreviation>Antibodies (Basel)</ISOAbbreviation></Journal><ArticleTitle>Long-Term Immunity against SARS-CoV-2 Wild-Type and Omicron XBB.1.5 in Indonesian Residents after Vaccination and Infection.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">72</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/antib13030072</ELocationID><Abstract><AbstractText>In the post-pandemic era, evaluating long-term immunity against COVID-19 has become increasingly critical, particularly in light of continuous SARS-CoV-2 mutations. This study aimed to assess the long-term humoral immune response in sera collected in Makassar. We measured anti-RBD IgG levels and neutralization capacity (NC) against both the Wild-Type (WT) Wuhan-Hu and Omicron XBB.1.5 variants across groups of COVID-19-vaccinated individuals with no booster (NB), single booster (SB), and double booster (DB). The mean durations since the last vaccination were 25.11 months, 19.24 months, and 16.9 months for the NB, SB, and DB group, respectively. Additionally, we evaluated the effect of breakthrough infection (BTI) history, with a mean duration since the last confirmed infection of 21.72 months. Our findings indicate fair long-term WT antibody (Ab) titers, with the DB group showing a significantly higher level than the other groups. Similarly, the DB group demonstrated the highest anti-Omicron XBB.1.5 Ab titer, yet it was insignificantly different from the other groups. Although the level of anti-WT Ab titers was moderate, we observed near-complete (96-97%) long-term neutralization against the WT pseudo-virus for all groups. There was a slight decrease in NC against Omicron XBB.1.5 compared to the WT among all groups, as DB group, SB group, and NB group showed 80.71 ± 3.9%, 74.29 ± 6.7%, and 67.2 ± 6.3% neutralization activity, respectively. A breakdown analysis based on infection and vaccine status showed that booster doses increase the NC against XBB.1.5, particularly in individuals without BTI. Individuals with BTI demonstrate a better NC compared to their counterpart uninfected individuals with the same number of booster doses. Our findings suggest that long-term immunity against SARS-CoV-2 persists and is effective against the mutant variant. Booster doses enhance the NC, especially among uninfected individuals.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karismananda</LastName><Identifier Source="ORCID">0009-0006-3504-6131</Identifier><AffiliationInfo><Affiliation>Master Program of Biomedical Science, Graduate School of Hasanuddin University, Makassar 90245, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasyim</LastName><ForeName>Ammar Abdurrahman</ForeName><Initials>AA</Initials><Identifier Source="ORCID">0000-0003-2799-1652</Identifier><AffiliationInfo><Affiliation>Laboratory of Vaccinology and Applied Immunology, Kanazawa University, Kanazawa 920-1192, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakamoto</LastName><ForeName>Akihiko</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0788-3646</Identifier><AffiliationInfo><Affiliation>Laboratory of Vaccinology and Applied Immunology, Kanazawa University, Kanazawa 920-1192, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamagata</LastName><ForeName>Kyouhei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Laboratory of Vaccinology and Applied Immunology, Kanazawa University, Kanazawa 920-1192, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zainal</LastName><ForeName>Kartika Hardianti</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Laboratory of Vaccinology and Applied Immunology, Kanazawa University, Kanazawa 920-1192, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suparman</LastName><ForeName>Desi Dwirosalia Ningsih</ForeName><Initials>DDN</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Faculty of Medicine, Bosowa University, Makassar 90232, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yustisia</LastName><ForeName>Ika</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0001-7611-968X</Identifier><AffiliationInfo><Affiliation>Master Program of Biomedical Science, Graduate School of Hasanuddin University, Makassar 90245, Indonesia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Faculty of Medicine, Hasanuddin University, Makassar 90245, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardjo</LastName><ForeName>Marhaen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Master Program of Biomedical Science, Graduate School of Hasanuddin University, Makassar 90245, Indonesia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Faculty of Medicine, Hasanuddin University, Makassar 90245, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kadir</LastName><ForeName>Syahrijuita</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Master Program of Biomedical Science, Graduate School of Hasanuddin University, Makassar 90245, Indonesia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Faculty of Medicine, Hasanuddin University, Makassar 90245, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iyori</LastName><ForeName>Mitsuhiro</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9940-7342</Identifier><AffiliationInfo><Affiliation>Research Institute of Pharmaceutical Sciences, Musashino University, Nishitokyo 202-8585, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Shigeto</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory of Vaccinology and Applied Immunology, Kanazawa University, Kanazawa 920-1192, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yusuf</LastName><ForeName>Yenni</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-7310-6381</Identifier><AffiliationInfo><Affiliation>Department of Parasitology, Faculty of Medicine, Hasanuddin University, Makassar 90245, Indonesia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>105/E4.4/KU/2021</GrantID><Agency>Indonesian Directorate General of Higher Education</Agency><Country /></Grant><Grant><GrantID>JPJSBP-120218101</GrantID><Agency>Japan Society for the Promotion of Science</Agency><Country /></Grant><Grant><GrantID>21K06559</GrantID><Agency>Grant-in-Aid for Scientific Research</Agency><Country /></Grant><Grant><GrantID>21K06545</GrantID><Agency>JSPS KAKENHI</Agency><Country /></Grant><Grant><GrantID>04966/UN4.22/PT.01.03/2023</GrantID><Agency>Institute of Research and Community Services Hasanuddin University</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Antibodies (Basel)</MedlineTA><NlmUniqueID>101587489</NlmUniqueID><ISSNLinking>2073-4468</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 vaccines</Keyword><Keyword MajorTopicYN="N">Omicron XBB.1.5</Keyword><Keyword MajorTopicYN="N">antibodies</Keyword><Keyword MajorTopicYN="N">immune persistence</Keyword><Keyword MajorTopicYN="N">neutralizing capacity</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>7</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39311377</ArticleId><ArticleId IdType="pmc">PMC11417924</ArticleId><ArticleId IdType="doi">10.3390/antib13030072</ArticleId><ArticleId IdType="pii">antib13030072</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization  Statement on the Fifteenth Meeting of the IHR (2005) Emergency Committee on the COVID-19 Pandemic.  [(accessed on 13 March 2024)].  Available online:  https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic.</Citation></Reference><Reference><Citation>COVID-19 Epidemiological Update. Dec 22, 2023.  [(accessed on 13 March 2024)].  Available online:  https://www.who.int/publications/m/item/covid-19-epidemiological-update---22-december-2023.</Citation></Reference><Reference><Citation>Healey Q., Sheikh A., Daines L., Vasileiou E. Symptoms and signs of long COVID: A rapid review and meta-analysis. J. Glob. Health. 2022;12:05014. doi: 10.7189/jogh.12.05014.</Citation><ArticleIdList><ArticleId IdType="doi">10.7189/jogh.12.05014</ArticleId><ArticleId IdType="pmc">PMC9125197</ArticleId><ArticleId IdType="pubmed">35596571</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau E.H.Y., Hui D.S.C., Tsang O.T.Y., Chan W.-H., Kwan M.Y.W., Chiu S.S., Cheng S.M.S., Ko R.L.W., Li J.K.C., Chaothai S., et al. Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection. eClinicalMedicine. 2021;41:101174. doi: 10.1016/j.eclinm.2021.101174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101174</ArticleId><ArticleId IdType="pmc">PMC8556690</ArticleId><ArticleId IdType="pubmed">34746725</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloomfield L.E., Ngeh S., Cadby G., Hutcheon K., Effler P.V. SARS-CoV-2 Vaccine Effectiveness against Omicron Variant in Infection-Naive Population, Australia, 2022. Emerg. Infect. Dis. J. 2023;29:6. doi: 10.3201/eid2906.230130.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2906.230130</ArticleId><ArticleId IdType="pmc">PMC10202853</ArticleId><ArticleId IdType="pubmed">37141626</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J., Hong W., Lei H., He C., Lei W., Zhou Y., Zhao T., Alu A., Ma X., Li J., et al. Low levels of neutralizing antibodies against XBB. Omicron subvariants after BA.5 infection. Signal Transduct. Target. Ther. 2023;8:252. doi: 10.1038/s41392-023-01495-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-023-01495-4</ArticleId><ArticleId IdType="pmc">PMC10279763</ArticleId><ArticleId IdType="pubmed">37336889</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyenla X.H., Bates T.A., Trank-Greene M., Wahedi M., Tafesse F.G., Curlin M. Evaluating Humoral Immunity Elicited by XBB.1.5 Monovalent COVID-19 Vaccine. Emerg. Infect. Dis. 2024;30:1282–1283. doi: 10.3201/eid3006.240051.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid3006.240051</ArticleId><ArticleId IdType="pmc">PMC11138983</ArticleId><ArticleId IdType="pubmed">38669121</ArticleId></ArticleIdList></Reference><Reference><Citation>Carr E.J., Wu M.Y., Gahir J., Harvey R., Townsley H., Bailey C., Fowler A.S., Dowgier G., Hobbs A., Herman L., et al. Neutralising immunity to omicron sublineages BQ.1.1, XBB., and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection. Lancet Infect. Dis. 2023;23:781–784. doi: 10.1016/S1473-3099(23)00289-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00289-X</ArticleId><ArticleId IdType="pmc">PMC10241485</ArticleId><ArticleId IdType="pubmed">37290472</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaeck L.M., Tan N.H., Rietdijk W.J.R., Geers D., Sablerolles R.S.G., Bogers S., van Dijk L.L.A., Gommers L., van Leeuwen L.P.M., Rugebregt S., et al. Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters. Nat. Commun. 2024;15:4224. doi: 10.1038/s41467-024-48414-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-48414-x</ArticleId><ArticleId IdType="pmc">PMC11102539</ArticleId><ArticleId IdType="pubmed">38762522</ArticleId></ArticleIdList></Reference><Reference><Citation>Indonesia K.K.R. Vaksinasi COVID-19 Nasional (National COVID-19 Vaccination)  [(accessed on 2 July 2024)].  Available online:  https://vaksin.kemkes.go.id/#/vaccines.</Citation></Reference><Reference><Citation>57 Million Indonesians Receive Third COVID-19 Vaccine Dose.  [(accessed on 14 March 2024)].  Available online:  https://en.antaranews.com/news/268248/6857-million-indonesians-receive-third-covid-19-vaccine-dose.</Citation></Reference><Reference><Citation>HAMASY A.I.A. Dua Warga DKI Jakarta Meninggal Akibat COVID-19.  [(accessed on 12 April 2024)].  Available online:  https://www.kompas.id/baca/metro/2023/12/11/dua-warga-dki-jakarta-meninggal-akibat-covid-19.</Citation></Reference><Reference><Citation>Ao D., He X., Hong W., Wei X. The rapid rise of SARS-CoV-2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants. MedComm. 2023;4:e239. doi: 10.1002/mco2.239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mco2.239</ArticleId><ArticleId IdType="pmc">PMC10015854</ArticleId><ArticleId IdType="pubmed">36938325</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J., Wang R., Gilby N.B., Wei G.-W. Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance. J. Chem. Inf. Model. 2022;62:412–422. doi: 10.1021/acs.jcim.1c01451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jcim.1c01451</ArticleId><ArticleId IdType="pmc">PMC8751645</ArticleId><ArticleId IdType="pubmed">34989238</ArticleId></ArticleIdList></Reference><Reference><Citation>Nurisyah S., Iyori M., Hasyim A.A., Sakamoto A., Hashimoto H., Yamagata K., Yamauchi S., Amru K., Zainal K.H., Idris I., et al. Comparison between Neutralization Capacity of Antibodies Elicited by COVID-19 Natural Infection and Vaccination in Indonesia: A Prospective Cohort. Antibodies. 2023;12:60. doi: 10.3390/antib12030060.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antib12030060</ArticleId><ArticleId IdType="pmc">PMC10526084</ArticleId><ArticleId IdType="pubmed">37753974</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakamoto A., Osawa H., Hashimoto H., Mizuno T., Hasyim A.A., Abe Y.-i., Okahashi Y., Ogawa R., Iyori M., Shida H., et al. A replication-competent smallpox vaccine LC16m8Δ-based COVID-19 vaccine. Emerg. Microbes Infect. 2022;11:2359–2370. doi: 10.1080/22221751.2022.2122580.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2122580</ArticleId><ArticleId IdType="pmc">PMC9527789</ArticleId><ArticleId IdType="pubmed">36069348</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H., Tang P., Hasan M.R., AlMukdad S., Yassine H.M., Benslimane F.M., Al Khatib H.A., Coyle P., Ayoub H.H., Al Kanaani Z., et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. N. Engl. J. Med. 2021;385:e83. doi: 10.1056/NEJMoa2114114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2114114</ArticleId><ArticleId IdType="pmc">PMC8522799</ArticleId><ArticleId IdType="pubmed">34614327</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H., Nagelkerke N., Ayoub H.H., Coyle P., Tang P., Yassine H.M., Al-Khatib H.A., Smatti M.K., Hasan M.R., Al-Kanaani Z., et al. Duration of immune protection of SARS-CoV-2 natural infection against reinfection. J. Travel Med. 2022;29:taac109. doi: 10.1093/jtm/taac109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jtm/taac109</ArticleId><ArticleId IdType="pmc">PMC9619565</ArticleId><ArticleId IdType="pubmed">36179099</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartof S.Y., Slezak J.M., Puzniak L., Hong V., Frankland T.B., Xie F., Ackerson B.K., Valluri S.R., Jodar L., McLaughlin J.M. Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: A test-negative, case-control study. Lancet Respir. Med. 2022;11:176–187. doi: 10.1016/S2213-2600(22)00354-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00354-X</ArticleId><ArticleId IdType="pmc">PMC9765328</ArticleId><ArticleId IdType="pubmed">36216013</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates T.A., Leier H.C., McBride S.K., Schoen D., Lyski Z.L., Xthona Lee D.D., Messer W.B., Curlin M.E., Tafesse F.G. An extended interval between vaccination and infection enhances hybrid immunity against SARS-CoV-2 variants. JCI Insight. 2023;8:165265. doi: 10.1172/jci.insight.165265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.165265</ArticleId><ArticleId IdType="pmc">PMC10077480</ArticleId><ArticleId IdType="pubmed">36701200</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumoto N., Sasaki A., Kadowaki T., Mitsuhashi T., Takao S., Yorifuji T. Longitudinal antibody dynamics after COVID-19 vaccine boosters based on prior infection status and booster doses. Sci. Rep. 2024;14:4564. doi: 10.1038/s41598-024-55245-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-55245-9</ArticleId><ArticleId IdType="pmc">PMC10894855</ArticleId><ArticleId IdType="pubmed">38403650</ArticleId></ArticleIdList></Reference><Reference><Citation>Underwood A.P., Sølund C., Fernandez-Antunez C., Signe Lysemose V., Mikkelsen L.S., Ulrik F., Bollerup S., Anni Assing W., Uffe Vest S., Binderup A., et al. Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination. eBioMedicine. 2023;89:104475. doi: 10.1016/j.ebiom.2023.104475.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2023.104475</ArticleId><ArticleId IdType="pmc">PMC9978324</ArticleId><ArticleId IdType="pubmed">36870117</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilenia V., Lai A., Fiaschi L., Bergna A., Gatti A., Caimi B., Biba C., Carla Della V., Balotta C., Riva A., et al. Neutralizing antibodies response to novel SARS-CoV-2 omicron sublineages in long-term care facility residents after the fourth dose of monovalent BNT162b2 COVID-19 vaccination. J. Infect. 2023;87:270–272. doi: 10.1016/j.jinf.2023.06.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2023.06.019</ArticleId><ArticleId IdType="pubmed">37394012</ArticleId></ArticleIdList></Reference><Reference><Citation>Varona J.F., Muñiz J., Balboa-Barreiro V., Peñalver F., Abarca E., Almirall C., Jose María C. Persistence and Waning of Natural SARS-CoV-2 Antibodies Over 18 Months: Long-Term Durability of IgG Humoral Response in Healthcare Workers. J. Gen. Intern. Med. 2022;37:2614–2616. doi: 10.1007/s11606-022-07652-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-022-07652-9</ArticleId><ArticleId IdType="pmc">PMC9113620</ArticleId><ArticleId IdType="pubmed">35581448</ArticleId></ArticleIdList></Reference><Reference><Citation>Korosec C.S., Dick D.W., Moyles I.R., Watmough J. SARS-CoV-2 Booster Vaccine Dose Significantly Extends Humoral Immune Response half-life beyond the Primary Series. Sci. Rep. 2024;14:8426. doi: 10.1038/s41598-024-58811-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-58811-3</ArticleId><ArticleId IdType="pmc">PMC11026522</ArticleId><ArticleId IdType="pubmed">38637521</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava K., Carreño J.M., Gleason C., Monahan B., Singh G., Abbad A., Tcheou J., Raskin A., Kleiner G., van Bakel H., et al. SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase. Immunity. 2024;57:587–599.e4. doi: 10.1016/j.immuni.2024.01.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2024.01.017</ArticleId><ArticleId IdType="pmc">PMC11066813</ArticleId><ArticleId IdType="pubmed">38395697</ArticleId></ArticleIdList></Reference><Reference><Citation>Curlin M.E., Bates T.A., Guzman G., Schoen D., McBride S.K., Carpenter S.D., Tafesse F.G. Omicron Neutralizing Antibody Response following Booster Vaccination Compared with Breakthrough Infection. Med. Xpress. 2022;3:827–837.e3. doi: 10.1016/j.medj.2022.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2022.09.001</ArticleId><ArticleId IdType="pmc">PMC9492511</ArticleId><ArticleId IdType="pubmed">36198311</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishiyama T., Miyamatsu Y., Park H., Nakamura N., Yokokawa Shibata R., Iwami S., Nagasaki Y. Modeling COVID-19 vaccine booster-elicited antibody response and impact of infection history. Vaccine. 2023;41:7655–7662. doi: 10.1016/j.vaccine.2023.11.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.11.040</ArticleId><ArticleId IdType="pubmed">38008663</ArticleId></ArticleIdList></Reference><Reference><Citation>Anshari Saifuddin H., Sukamto K., Widhani A., Muhadi M., Hamzah S., Eka G., Evy Y., Pradana S., Sally Aman N., Samsuridjal D., et al. Incidence and Associated Factors of SARS-CoV-2 Infection Post-mRNA-1273 Booster Vaccination in Health-Care Workers. Vaccines. 2023;11:481. doi: 10.3390/vaccines11020481.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11020481</ArticleId><ArticleId IdType="pmc">PMC9963908</ArticleId><ArticleId IdType="pubmed">36851358</ArticleId></ArticleIdList></Reference><Reference><Citation>Glück V., Grobecker S., Köstler J., Tydykov L., Bertok M., Weidlich T., Gottwald C., Salzberger B., Wagner R., Zeman F., et al. Immunity after COVID-19 and vaccination: Follow-up study over 1 year among medical personnel. Infection. 2021;38:439–446. doi: 10.1007/s15010-021-01703-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-021-01703-9</ArticleId><ArticleId IdType="pmc">PMC8475821</ArticleId><ArticleId IdType="pubmed">34562263</ArticleId></ArticleIdList></Reference><Reference><Citation>Abebe E.C., Dejenie T.A. Protective Roles and Protective Mechanisms of Neutralizing Antibodies against SARS-CoV-2 Infection and Their Potential Clinical Implications. Front. Immunol. 2023;14:1055457. doi: 10.3389/fimmu.2023.1055457.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1055457</ArticleId><ArticleId IdType="pmc">PMC9892939</ArticleId><ArticleId IdType="pubmed">36742320</ArticleId></ArticleIdList></Reference><Reference><Citation>Burton D.R. Antiviral Neutralizing antibodies: From in Vitro to in Vivo Activity. Nat. Rev. Immunol. 2023;23:720–734. doi: 10.1038/s41577-023-00858-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-023-00858-w</ArticleId><ArticleId IdType="pmc">PMC10108814</ArticleId><ArticleId IdType="pubmed">37069260</ArticleId></ArticleIdList></Reference><Reference><Citation>Harapan H., Hibban Ar R., Islam Ing T., Auda N., Irham Faraby A., Anwar S., Husnah M., Ichsan I., Agung P., Mudatsir M., et al. Waning anti-SARS-CoV-2 receptor-binding Domain Total Antibody in CoronaVac-vaccinated Individuals in Indonesia. F1000Research. 2023;11:300. doi: 10.12688/f1000research.109676.2.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.109676.2</ArticleId><ArticleId IdType="pmc">PMC10209622</ArticleId><ArticleId IdType="pubmed">37260419</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore S.C., Kronsteiner B., Longet S., Adele S., Deeks A.S., Liu C., Dejnirattisai W., Reyes L.S., Meardon N., Faustini S., et al. Evolution of long-term vaccine-induced and Hybrid Immunity in Healthcare Workers after Different COVID-19 Vaccine Regimens. Med. 2023;4:191–215.e9. doi: 10.1016/j.medj.2023.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2023.02.004</ArticleId><ArticleId IdType="pmc">PMC9933851</ArticleId><ArticleId IdType="pubmed">36863347</ArticleId></ArticleIdList></Reference><Reference><Citation>Kannikar I., Suwat C., Kittipan C., Thanachol W., Woravut K., Aksara T., Narain C., Kajohnsak N., Krit K., Worachet T., et al. Heterologous Booster Vaccines Reduce Severity and Mortality in COVID-19 during BA.2 and BA.4/BA.5 Omicron Predominance in Thailand. Wēi-Miǎn Yǔ Gǎnrǎn Zázhì/J. Microbiol. Immunol. Infect. 2023;56:1178–1186. doi: 10.1016/j.jmii.2023.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2023.10.001</ArticleId><ArticleId IdType="pubmed">37880062</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales-Núñez J.J., Muñoz-Valle J.F., Torres-Hernández P.C., Hernández-Bello J. Overview of Neutralizing Antibodies and Their Potential in COVID-19. Vaccines. 2021;9:1376. doi: 10.3390/vaccines9121376.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9121376</ArticleId><ArticleId IdType="pmc">PMC8706198</ArticleId><ArticleId IdType="pubmed">34960121</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi X., Yan R., Zhang J., Zhang G., Zhang Y., Hao M., Zhang Z., Fan P., Dong Y., Yang Y., et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science. 2020;369:650–655. doi: 10.1126/science.abc6952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc6952</ArticleId><ArticleId IdType="pmc">PMC7319273</ArticleId><ArticleId IdType="pubmed">32571838</ArticleId></ArticleIdList></Reference><Reference><Citation>Favresse J., Gillot C., Cabo J., David C., Dogné J.-M., Douxfils J. Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster. Int. J. Infect. Dis. 2024;143:107028. doi: 10.1016/j.ijid.2024.107028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2024.107028</ArticleId><ArticleId IdType="pubmed">38583825</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain S., Naseer F., Kanani F., Javeria A. Evaluating long-term Antibody Responses to Booster Doses of COVID-19 Vaccines in the Pakistani Population. Pak. J. Med. Sci. 2023;40:S28. doi: 10.12669/pjms.40.2(ICON).8951.</Citation><ArticleIdList><ArticleId IdType="doi">10.12669/pjms.40.2(ICON).8951</ArticleId><ArticleId IdType="pmc">PMC10844906</ArticleId><ArticleId IdType="pubmed">38328653</ArticleId></ArticleIdList></Reference><Reference><Citation>Terbsiri V., Putcharoen O., Suwanpimolkul G., Jantarabenjakul W., Wacharapluesadee S., Champa N., Thippamom N., Paitoonpong L. Long-term Immunogenicity in Previously Vaccinated Healthcare Workers with Inactivated Virus Vaccine after SARS-CoV-2 Infection or Booster Vaccination. Vaccine X. 2023;14:100334. doi: 10.1016/j.jvacx.2023.100334.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvacx.2023.100334</ArticleId><ArticleId IdType="pmc">PMC10281697</ArticleId><ArticleId IdType="pubmed">37361052</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Y., Pan J., Jin M., Wang J., Tung T.-H., Chen S., Bi X., Zhou K., Chen M., Wang D., et al. Efficacy of the Neutralizing Antibodies after the Booster Dose on SARS-CoV-2 Omicron Variant and a two-year Longitudinal Antibody Study on Wild Type Convalescents. Int. Immunopharmacol. 2023;119:110151. doi: 10.1016/j.intimp.2023.110151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2023.110151</ArticleId><ArticleId IdType="pmc">PMC10073579</ArticleId><ArticleId IdType="pubmed">37044040</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Liu J., Zou J., Kalveram B., Machado R.R.G., Ren P., Türeli S., Smith D.J., Weaver S.C., Xie X., et al. Cross-neutralization and cross-protection among SARS-CoV-2 Viruses Bearing Different Variant Spikes. Signal Transduct. Target. Ther. 2022;7:285. doi: 10.1038/s41392-022-01137-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-01137-1</ArticleId><ArticleId IdType="pmc">PMC9375067</ArticleId><ArticleId IdType="pubmed">35963863</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawford K.H.D., Dingens A.S., Eguia R., Wolf C.R., Wilcox N., Logue J.K., Shuey K., Casto A.M., Fiala B., Wrenn S., et al. Dynamics of Neutralizing Antibody Titers in the Months after Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J. Infect. Dis. 2020;223:197–205. doi: 10.1093/infdis/jiaa618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa618</ArticleId><ArticleId IdType="pmc">PMC7543487</ArticleId><ArticleId IdType="pubmed">33535236</ArticleId></ArticleIdList></Reference><Reference><Citation>Wajnberg A., Amanat F., Firpo A., Altman D.R., Bailey M.J., Mansour M., McMahon M., Meade P., Mendu D.R., Muellers K., et al. Robust Neutralizing Antibodies to SARS-CoV-2 Infection Persist for Months. Science. 2020;370:1227–1230. doi: 10.1126/science.abd7728.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd7728</ArticleId><ArticleId IdType="pmc">PMC7810037</ArticleId><ArticleId IdType="pubmed">33115920</ArticleId></ArticleIdList></Reference><Reference><Citation>Shim S.-M., Kim J.-W., Jung S., Jung Y., Woo H.-M., Yang J.-S., Kim K.-C., Lee J.-Y. Persistence of the Neutralizing Antibody Response after SARS-CoV-2 Infection. Clin. Microbiol. Infect. 2021;28:614.e1–614.e4. doi: 10.1016/j.cmi.2021.12.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.12.012</ArticleId><ArticleId IdType="pmc">PMC8695319</ArticleId><ArticleId IdType="pubmed">34954127</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y., Wang F., Shen C., Peng W., Li D., Zhao C., Li Z., Li S., Bi Y., Yang Y., et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. 2020;368:1274–1278. doi: 10.1126/science.abc2241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc2241</ArticleId><ArticleId IdType="pmc">PMC7223722</ArticleId><ArticleId IdType="pubmed">32404477</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheward D.J., Kim C., Ehling R.A., Pankow A., Castro Dopico X., Dyrdak R., Martin D.P., Reddy S.T., Dillner J., Karlsson Hedestam G.B., et al. Neutralisation Sensitivity of the SARS-CoV-2 Omicron (B.1.1.529) variant: A cross-sectional Study. Lancet Infect. Dis. 2022;22:813–820. doi: 10.1016/S1473-3099(22)00129-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00129-3</ArticleId><ArticleId IdType="pmc">PMC8930016</ArticleId><ArticleId IdType="pubmed">35305699</ArticleId></ArticleIdList></Reference><Reference><Citation>da Silva E.S., Kohnen M., Gilson G., Staub T., Arendt V., Hilger C., Servais J.-Y., Charpentier E., Domingues O., Snoeck C.J., et al. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone. Int. J. Mol. Sci. 2022;23:7675. doi: 10.3390/ijms23147675.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23147675</ArticleId><ArticleId IdType="pmc">PMC9320437</ArticleId><ArticleId IdType="pubmed">35887023</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamatatos L., Czartoski J., Wan Y.-H., Homad L.J., Rubin V., Glantz H., Neradilek M., Seydoux E., Jennewein M.F., MacCamy A.J., et al. MRNA Vaccination Boosts cross-variant Neutralizing Antibodies Elicited by SARS-CoV-2 Infection. Science. 2021;372:1413–1418. doi: 10.1126/science.abg9175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abg9175</ArticleId><ArticleId IdType="pmc">PMC8139425</ArticleId><ArticleId IdType="pubmed">33766944</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu X., Qi X., Cao Y., Li P., Lu L., Wang P., Feng Y., Yang J., Wei H., Guo L., et al. Three Doses of an inactivation-based COVID-19 Vaccine Induces cross-neutralizing Immunity against the SARS CoV-2 Omicron Variant. Emerg. Microbes Infect. 2022;11:749–752. doi: 10.1080/22221751.2022.2044271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2044271</ArticleId><ArticleId IdType="pmc">PMC8903785</ArticleId><ArticleId IdType="pubmed">35176972</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu P., Faraone J.N., Evans J.P., Zheng Y.-M., Carlin C., Anghelina M., Stevens P., Fernandez S., Jones D., Panchal A.R., et al. Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants. Cell Rep. 2023;42:112443. doi: 10.1016/j.celrep.2023.112443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2023.112443</ArticleId><ArticleId IdType="pmc">PMC10279473</ArticleId><ArticleId IdType="pubmed">37104089</ArticleId></ArticleIdList></Reference><Reference><Citation>Dapporto F., Marchi S., Leonardi M., Piu P., Lovreglio P., Decaro N., Buonvino N., Stufano A., Lorusso E., Bombardieri E., et al. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination. J. Immunol. Res. 2022;2022:4813199. doi: 10.1155/2022/4813199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/4813199</ArticleId><ArticleId IdType="pmc">PMC9453088</ArticleId><ArticleId IdType="pubmed">36093434</ArticleId></ArticleIdList></Reference><Reference><Citation>Prather A.A., Dutcher E.G., Robinson J., Lin J., Blackburn E., Hecht F.M., Mason A.E., Fromer E., Merino B., Frazier R., et al. Predictors of long-term neutralizing antibody titers following COVID-19 vaccination by three vaccine types: The BOOST study. Sci. Rep. 2023;13:6505. doi: 10.1038/s41598-023-33320-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-33320-x</ArticleId><ArticleId IdType="pmc">PMC10170073</ArticleId><ArticleId IdType="pubmed">37160978</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>